Risk of assisted reproductive technology failure with individual anti-phospholipid antibodies
| Antibody . | No. of studies (no. of patients) . | OR (95% CI) . | I2, % (P) . |
|---|---|---|---|
| Lupus anticoagulant | 12 (2013) | 5.60 (2.16-14.55) | 0 (.80) |
| Anti-cardiolipin | 15 (2685) | 3.27 (0.92-11.63) | 76 (< .001) |
| Anti-phosphatidylserine | 3 (820) | 4.51 (1.37-14.80) | 0 (.46) |
| Anti-phosphatidylinositol | 2 (408) | 5.03 (1.13-22.47) | 0 (.82) |
| Anti-phosphatidic acid | 1 (394) | 4.65 (1.10-19.74) | — |
| Anti-phosphatidylglycerol | 1 (394) | 2.77 (1.06-7.20) | — |
| Anti–β2-glycoprotein I | 3 (574) | 1.19 (0.39-3.67) | — |
| Antiphosphatidylethanolamine | 2 (408) | 1.31 (0.46-3.71) | 70 (.27) |
| Antibody . | No. of studies (no. of patients) . | OR (95% CI) . | I2, % (P) . |
|---|---|---|---|
| Lupus anticoagulant | 12 (2013) | 5.60 (2.16-14.55) | 0 (.80) |
| Anti-cardiolipin | 15 (2685) | 3.27 (0.92-11.63) | 76 (< .001) |
| Anti-phosphatidylserine | 3 (820) | 4.51 (1.37-14.80) | 0 (.46) |
| Anti-phosphatidylinositol | 2 (408) | 5.03 (1.13-22.47) | 0 (.82) |
| Anti-phosphatidic acid | 1 (394) | 4.65 (1.10-19.74) | — |
| Anti-phosphatidylglycerol | 1 (394) | 2.77 (1.06-7.20) | — |
| Anti–β2-glycoprotein I | 3 (574) | 1.19 (0.39-3.67) | — |
| Antiphosphatidylethanolamine | 2 (408) | 1.31 (0.46-3.71) | 70 (.27) |
— indicates not applicable.